Drug Trial Radar · NCT02265913
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
Last checked: Nov 19, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,076
Actual
Start
Oct 6, 2014
Primary completion
Apr 27, 2016
Study completion Nov 21, 2017
Sponsor
- Lead sponsor
- Padagis LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
Conditions
- Herpes Labialis
Interventions
Acyclovir 5 percent (Perrigo)Drug
Acyclovir 5 percent (Reference)Drug
Placebo creamDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lesion HealingTime frame: up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quality Clinical Research Inc
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.